Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
BIOFILCHEM

Biofil Chemicals & Pharmaceuticals Share Price

 
Stock Result Declared

 

Biofil Chemicals & Pharmaceuticals live price: ₹35.09. It opened at ₹37 vs previous close ₹36; intraday high/low: ₹37/₹35. The 50 & 200 DMA stand at ₹32.98/₹36.69.

Biofil Chemicals & Pharmaceuticals Performance

  • Today's Low
  • ₹35
  • Today's High
  • ₹37
  • 52 Week Low
  • ₹26
  • 52 Week High
  • ₹57
  • Open Price₹37
  • Previous Close₹36
  • Volume32,236
  • 50 DMA₹32.98
  • 100 DMA₹33.65
  • 200 DMA₹36.69

Biofil Chemicals & Pharmaceuticals Chart

Investment Returns

  • Over 1 Month + 4.25%
  • Over 3 Month + 9.52%
  • Over 6 Month -5.75%
  • Over 1 Year -30.99%

Smart Investing Starts Here Start SIP with Biofil Chemicals & Pharmaceuticals for Steady Growth!

Invest Now

Biofil Chemicals & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 20.5
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 57
  • P/B Ratio
  • 2.7
  • Average True Range
  • 2.16
  • EPS
  • 1.7
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.13
  • RSI
  • 59.09
  • MFI
  • 92.13

Biofil Chemicals & Pharmaceuticals Financials

Biofil Chemicals & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹35.09
-0.53 (-1.49%)
pointer
  • Bearish Moving Average 2
  • Bullish Moving Average 14
  • 20 Day
  • ₹33.36
  • 50 Day
  • ₹32.98
  • 100 Day
  • ₹33.65
  • 200 Day
  • ₹36.69

Resistance and Support

35.58 Pivot Speed
  • R3 38.41
  • R2 37.63
  • R1 36.36
  • S1 34.31
  • S2 33.53
  • S3 32.26

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Biofil Chemicals & Pharmaceuticals has an operating revenue of Rs. 29.18 Cr. on a trailing 12-month basis. An annual revenue de-growth of -17% needs improvement, Pre-tax margin of 2% needs improvement, ROE of 2% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and around 10% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 49 which is a POOR score indicating inconsistency in earnings, a RS Rating of 45 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 36 indicates it belongs to a strong industry group of Medical-Ethical Drugs and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Biofil Chemicals & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-30 Audited Results
2026-02-13 Quarterly Results
2025-11-13 Quarterly Results
2025-08-12 Quarterly Results
2025-05-30 Audited Results

Biofil Chemicals & Pharmaceuticals Shareholding Pattern

46.79%
0%
0.04%
38.4%
14.77%

Biofil Chemicals & Pharmaceuticals FAQs

Biofil Chemicals & Pharmaceuticals share price is ₹35 As on 31 May, 2026 | 05:03

The Market Cap of Biofil Chemicals & Pharmaceuticals is ₹57.1 Cr As on 31 May, 2026 | 05:03

The P/E ratio of Biofil Chemicals & Pharmaceuticals is 20.5 As on 31 May, 2026 | 05:03

The PB ratio of Biofil Chemicals & Pharmaceuticals is 2.7 As on 31 May, 2026 | 05:03

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23